Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance

Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance

Yao M, Jiang X, Xiao F, Lv X, Sheng M, Xing W, Bai J, Zhou Y. Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance. Cancer Lett. 2024 May 8;593:216949.

Used in this study:immunodeficient B-NDG mice

Read entire article

Share:

Back to top